Hexarelin is a synthetic growth-hormone-secretagogue-receptor (GHSR) agonist used in endocrine-signaling and receptor-pharmacology models. The original overview of this page asks three questions: GHSR agonism and endocrine-model context, distinguishing hexarelin from GHRH analogues, and LC-MS identity and HPLC purity review.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
GHSR agonism and endocrine-model context
Deghenghi and colleagues described hexarelin as a new growth hormone-releasing peptide and reported GH-releasing activity in infant and adult rats (Deghenghi et al., 1994). That identity places hexarelin in the GHSR / GHRP family, with ipamorelin, not in the GHRH-receptor family used by sermorelin, CJC-1295, or tesamorelin. See What Is Ipamorelin? and CJC-1295 vs Sermorelin vs Ipamorelin.
A “GH-releasing peptide” family name is not a specification. Hexarelin should not be filed as if it were a GHRH fragment or a DAC-bearing analogue.
Published observations — and their limits
The Deghenghi paper reports GH-releasing activity in the rat models they described. Those are published animal-model observations. They are not a human protocol, they do not provide administration guidance, and they do not describe a current catalog lot. Results reported for hexarelin should not be transferred automatically to ipamorelin or to a GHRH analogue.
LC-MS identity and HPLC purity review
A useful quality review still separates sequence identity, purity, content, and lot matching. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply independently to this row.
Hexarelin was not found as a standalone published item in Velnacor’s current research-material catalog listing used for this draft. Use the product directory and the COA Library, then confirm whether a current SKU exists and which lot documents apply in the inquiry. For packing at supply scale, see wholesale peptides.
A GHSR-agonist file and a GHRH-analogue file answer different receptor questions. Sermorelin, CJC-1295, and tesamorelin belong to the latter family; ipamorelin belongs to the former, with hexarelin. Results, certificates, and names should be kept in those families and not merged because a catalog heading says “growth hormone research.” If a quotation uses a related GHRP synonym, the sequence, salt form if stated, and the report still have to agree before the material is accepted as hexarelin.
Mass confirmation and a purity chromatogram are complementary, not interchangeable. A percentage on an HPLC trace does not, by itself, identify the analyte, and a mass value does not, by itself, establish purity. Quantity, residual-solvent or contaminant records when they are provided, and the lot number on the vial should be read against the same certificate. Those checks are documentation practices. This page does not prescribe a reconstitution or assay procedure.
Selected published literature
- Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences. 1994;54(18):1321-1328. doi:10.1016/0024-3205(94)00510-9. PubMed 7910650.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.